Provided by Tiger Trade Technology Pte. Ltd.

ZYMEWORKS INC (US)

28.67
+2.107.90%
Post-market: 28.940.2700+0.94%19:40 EDT
Volume:836.38K
Turnover:23.54M
Market Cap:2.03B
PE:-14.19
High:28.74
Open:26.97
Low:26.77
Close:26.57
52wk High:29.75
52wk Low:13.60
Shares:70.96M
Float Shares:66.05M
Volume Ratio:1.51
T/O Rate:1.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0200
EPS(LYR):-1.0800
ROE:-72.31%
ROA:-24.14%
PB:25.31
PE(LYR):-26.55

Loading ...

Zymeworks is Maintained at Buy by Truist Securities

Dow Jones
·
Jul 07

Zymeworks Said to Near $929 Million Deal for Theravance - Bloomberg News

Reuters
·
Jul 03

Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX), Taysha Gene Therapies (TSHA) and Zymeworks (ZYME)

TIPRANKS
·
Jul 01

PRESS Digest-canada - June 30

Reuters
·
Jun 30

Analysts Are Bullish on Top Healthcare Stocks: BioCryst (BCRX), Zymeworks (ZYME)

TIPRANKS
·
Jun 30

Zymeworks, Inc. : Wells Fargo Raises Target Price to $37 from $34

THOMSON REUTERS
·
Jun 30

Zymeworks price target raised to $37 from $35 at Citi

TIPRANKS
·
Jun 30

Zymeworks Down 6.1%

THOMSON REUTERS
·
Jun 29

Zymeworks Posts Investor Presentation on Planned Theravance Biopharma Acquisition for Yupelri Cash Flows

Reuters
·
Jun 29

Deals of the Day-mergers and Acquisitions

Reuters
·
Jun 29

Why This Biotech Stock is Falling After a $929 Million Buyout Lifeline

Dow Jones
·
Jun 29

Theravance Biopharma: Co to Pay $32.5 Mln Termination Fee to Zymeworks, if Deal Terminated Under Certain Circumstances

THOMSON REUTERS
·
Jun 29

Theravance Biopharma to be acquired by Zymeworks for $17.00 per share in cash

TIPRANKS
·
Jun 29

Theravance Biopharma Shares Fall 3.3% Premarket; Co to be Acquired by Zymeworks for $17 Per Share in Cash Plus a Contingent Value Right

THOMSON REUTERS
·
Jun 29

Zymeworks to Acquire Theravance Biopharma for USD 17 Per Share in USD 929 Million Deal

Reuters
·
Jun 29

Theravance Biopharma - Strategic Review Committee and Board Unanimously Approve and Recommend Deal

THOMSON REUTERS
·
Jun 29

Theravance Biopharma - Deal Represents Equity Value of About $929 Mln

THOMSON REUTERS
·
Jun 29

Theravance Biopharma - to be Bought by Zymeworks for $17 Per Share in Cash Plus CVR

THOMSON REUTERS
·
Jun 29

Theravance Biopharma - Shareholders to Receive CVR for 80% of Net Proceeds from Ampreloxetine Monetization

THOMSON REUTERS
·
Jun 29

Zymeworks - Deal Financed by $350 Mln Non-recourse Note, $360 Mln Net Cash, $219 Mln Zymeworks Cash

THOMSON REUTERS
·
Jun 29